Advertisement
Australia markets close in 2 hours 29 minutes

  • ALL ORDS

    7,781.70
    -117.20 (-1.48%)
     

  • ASX 200

    7,532.40
    -109.70 (-1.44%)
     

  • AUD/USD

    0.6394
    -0.0032 (-0.49%)
     

  • OIL

    84.80
    +2.07 (+2.50%)
     

  • GOLD

    2,402.40
    +4.40 (+0.18%)
     

  • Bitcoin AUD

    96,588.18
    -638.26 (-0.66%)
     

  • CMC Crypto 200

    1,280.81
    +395.27 (+43.14%)
     

  • AUD/EUR

    0.6008
    -0.0023 (-0.38%)
     

  • AUD/NZD

    1.0872
    -0.0002 (-0.02%)
     

  • NZX 50

    11,738.74
    -97.30 (-0.82%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,123.72
    -262.15 (-1.60%)
     

  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

Generation Bio Co.
·1-min read

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022.

Presentation Details
Date: Wednesday, Jan. 12, 2022
Time: 8:15-8:55 a.m. ET

A live webcast of the company presentation and Q&A session will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

ADVERTISEMENT

For more information, please visit www.generationbio.com.

Contact:

Investors
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420

Media

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783